T. Rowe Price Investment Management, Inc. Xenon Pharmaceuticals Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,426,339 shares of XENE stock, worth $52.5 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
1,426,339
Previous 891,149
60.06%
Holding current value
$52.5 Million
Previous $41 Million
49.59%
% of portfolio
0.04%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding XENE
# of Institutions
228Shares Held
69MCall Options Held
307KPut Options Held
68.9K-
Avoro Capital Advisors LLC New York, NY5.67MShares$209 Million2.94% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.32MShares$159 Million2.04% of portfolio
-
Wellington Management Group LLP Boston, MA3.92MShares$144 Million0.03% of portfolio
-
Capital World Investors Los Angeles, CA2.68MShares$98.7 Million0.02% of portfolio
-
Polar Capital Holdings PLC London, X02.61MShares$96.2 Million0.7% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.29B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...